重要资讯 1、中国人民银行召开2026年工作会议，强调继续实施适度宽松的货币政策，把促进经济高质量发展、 物价合理回升作为货币政策的重要考量，灵活高效运用降准降息等多种货币政策工具。同时再次提及了 备受市场关注的"向非银机构提供流动性的机制性安排"一事，央行通稿中提出"建立在特定情景下向非 银机构提供流动性的机制性安排，发挥好两项支持资本市场的货币政策工具作用"。 2、上海市发布20条措施鼓励外商投资企业境内再投资，支持企业按规定申请国家超长期特别国债，在 重点领域开展大规模设备更新项目投资，取消外商投资性公司使用境内贷款限制。 2、中国医药拟以5.25亿元现金收购上海则正医药70%股权，交易完成后则正医药将成为其控股子公 司，旨在提升医药研发创新领域综合实力。 3、蓝思科技是强脑科技的战略投资者，独家承接了其核心硬件模组的量产。 4、圣阳股份拟以7447.08万元收购深圳达人高科电子有限公司51%股权，以拓展储能BMS布局。 5、紫金矿业因有色金属等价格上涨，2025年业绩预增等因素，股价连涨四天，市值首次突破万亿元大 关。 6、创远信科并购重组材料被北交所正式受理，拟收购微宇天导100%股权。 3、国家外 ...

观想科技公告称，拟通过发行股份及支付现金方式购买锦州辽晶电子科技股份有限公司100%股份并募 集配套资金。公司就本次交易制定严格有效的保密制度，采取充分必要保密措施，及时向深交所申请股 票停牌，与中介机构签保密协议，登记报送内幕信息知情人档案，告知交易相关方严格保密，不存在违 法违规公开或泄露交易信息情况。 ...

Core Viewpoint - Weigao Blood Purification plans to acquire 100% equity of Weigao Purui for a total transaction amount of 8.511 billion yuan, which will enhance its product line into pharmaceutical packaging materials and expand its market presence in the biopharmaceutical upstream business [1][2]. Group 1: Acquisition Details - The acquisition will be executed through a share issuance priced at 31.29 yuan per share, with approximately 272 million shares to be issued, representing 39.43% of the total share capital post-issuance [1]. - After the transaction, Weigao Blood Purification's controlling shareholder will change from Weigao Group to Weigao Co., which will hold an 84.36% stake, maintaining the actual controller as Chen Xueli [1]. Group 2: Financial Performance of Weigao Purui - Weigao Purui has a strong market position, holding over 50% of the domestic market share for pre-filled products from 2022 to 2024, ranking first in the industry [2]. - The company has demonstrated robust profitability, with projected revenues of 1.426 billion yuan, 1.684 billion yuan, and 939 million yuan for 2023 to the first half of 2025, and net profits of 490 million yuan, 585 million yuan, and 327 million yuan for the same periods [2]. Group 3: Weigao Blood Purification's Business Overview - Weigao Blood Purification is a leading enterprise in the blood purification field, focusing on the R&D and production of blood dialysis devices and related products [2]. - The company has shown steady performance, with total revenue of 2.736 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 3.45%, and a net profit of 341 million yuan, up 7.92%, with a gross margin of 40.69% [2]. Group 4: Future Projections - Following the acquisition, Weigao Blood Purification's profitability is expected to improve significantly, with projected increases in revenue and net profit of 51.56% and 142.57%, respectively, for the first three quarters of 2025, and total assets anticipated to reach 12.044 billion yuan [2].

公告显示，威高普瑞主营业务为预灌封给药系统及自动安全给药系统等医药包材的研发、生产与销售。 威高血净表示，本次交易前，公司主要从事血液净化领域医用制品的研发、生产和销售，并已基于自身 技术平台完成了中空纤维病毒过滤器等生物制药滤器的技术研发与产品试制。本次交易后，公司主营业 务将新增预灌封给药系统及自动安全给药系统等医药包材的研发、生产与销售。本次交易完成后，公司 可以通过整合标的公司技术积累和产品布局，将产品线扩展到医药包材领域。同时，本次交易完成后， 通过充分协同公司自身中空纤维过滤技术优势与标的公司在生物制药领域的丰富客户资源，可以实现双 方在生物制药滤器业务上技术储备与客户资源的双向赋能，共同开拓以生物制药滤器为重点的生物制药 上游业务市场。 北京商报讯（记者 丁宁）1月5日晚间，威高血净（603014）发布重组草案显示，公司拟发行股份购买 山东威高普瑞医药包装有限公司（以下简称"威高普瑞"）100%股权，交易价格约为85.11亿元。 ...

Core Viewpoint - Meike Home (600337.SH) resumed trading on January 5, 2026, with a closing price of 3.21 yuan, reflecting a 9.93% increase following the announcement of a planned acquisition of Shenzhen Wandeng Technology Co., Ltd. [1][2] Group 1: Transaction Details - Meike Home plans to acquire 100% equity of Wandeng Technology through a combination of issuing shares and cash payments, while also raising supporting funds from no more than 35 specific investors [2][3] - The share issuance price for the acquisition is set at 1.94 yuan per share, which is not less than 80% of the average trading price over the previous 120 trading days [3] - The total amount of supporting funds to be raised will not exceed 100% of the transaction price for the asset acquisition, with the number of shares issued capped at 30% of the company's total share capital prior to the transaction [3] Group 2: Financial Performance of Target Company - As of December 31, 2023, the total assets of Wandeng Technology were 20.63 million yuan, with total liabilities of 16.28 million yuan and shareholders' equity of 4.35 million yuan [5] - The company reported total revenues of 45.98 million yuan in 2022, 41.82 million yuan in 2023, and 33.95 million yuan in 2024, with net profits of -28.9 million yuan, -46.3 million yuan, and -86.4 million yuan respectively [5] Group 3: Strategic Implications - The acquisition is expected to facilitate Meike Home's strategic transformation, expanding new business growth points and enhancing operational quality and profitability [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688173 证券简称：希荻微 公告编号：2026-001 希荻微电子集团股份有限公司 第二届董事会第二十九次会议 决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 希荻微电子集团股份有限公司（以下简称"公司"）第二届董事会第二十九次会议于2025年12月23日以通 讯方式和书面方式发出通知，并于2025年12月31日以现场及通讯表决方式召开。本次会议由公司董事长 TAO HAI（陶海）先生主持，会议应参加表决的董事为8人，实际参加会议表决的董事为8人。本次会 议的召集、召开和表决程序符合《中华人民共和国公司法》和《希荻微电子集团股份有限公司章程》的 有关规定，会议决议合法、有效。 二、董事会审议情况 会议以记名投票表决方式，审议通过了以下议案： （一）审议通过《关于调整购买资产方案的议案》 为加快交易进程、提高交易效率，经审慎考虑并经交易各方协商，公司拟撤回以发行股份及支付现金的 方式购买深圳市诚芯微科技股份有限公司（以下简称"诚 ...

根据银信资产评估有限公司出具的评估报告，以2025年6月30日为评估基准日，诚芯微股东全部权益价 值评估值为3.12亿元。参考上述评估值，经交易各方友好协商一致，诚芯微100%股份的交易价格确定 为3.1亿元。交易完成后，诚芯微将成为希荻微的全资子公司，并纳入公司合并报表范围。 根据公告，本次交易的业绩承诺期为2025年度、2026年度及2027年度，共计3个会计年度。诚芯微于前 述年度实现的净利润分别不低于2200万元、2500万元和2800万元，3年共实现净利润不低于7500万元。 希荻微在公告中指出，公司与诚芯微同属集成电路设计行业，公司可通过本次交易快速吸收标的公司成 熟的专利技术、研发资源、销售渠道和客户资源等，快速扩大公司的产品品类，从而有利于公司拓宽在 电源管理芯片、电机类芯片、MOSFET和电池管理芯片等领域的技术与产品布局，为更多下游细分行业 客户提供更为完整的解决方案和对应的产品。 （文章来源：证券日报） 1月1日，希荻微电子集团股份有限公司（以下简称"希荻微"）发布公告称，对收购深圳市诚芯微科技股 份有限公司（以下简称"诚芯微"）的方案进行调整，计划撤回发行股份及支付现金购买诚芯微100 ...

Core Viewpoint - Netflix's stock has declined by 17% over the past month due to a significant and risky strategic acquisition, leading investors to reevaluate the company's valuation [1] Acquisition Details - In early December, Netflix announced a deal to acquire Warner Bros.' studio and streaming assets, valuing the assets at approximately $72 billion in equity and $82.7 billion in enterprise value [2] - The acquisition is complex and contingent on Warner Bros. Discovery completing a separation of its Global Networks business, expected by Q3 2026 [6] Investor Sentiment - Investors are cautious about the deal due to its complexity and the uncertainty surrounding its closure, which Netflix anticipates will take 12 to 18 months [3][6] - Competing bidders have emerged, adding to the uncertainty and investor caution [7] Operational Complexity - Netflix plans to maintain Warner Bros.' current operations, which will increase operational complexity [8] - The company projects annual cost savings of $2 billion to $3 billion by the third year and expects the acquisition to be accretive to GAAP earnings per share by the second year [8] Business Performance - Despite the acquisition news, Netflix's third-quarter revenue grew by 17% year over year, with expectations for continued growth into Q4 [10] - The advertising business is also on track to more than double its revenue by 2025, indicating strong growth potential [11] Content Success - Netflix's "Stranger Things" has shown strong performance, with seasons 1 through 4 attracting over 1.2 billion viewers, and season 5 volume 1 garnering nearly 103 million views in just four weeks [12] Valuation Concerns - Netflix's stock is considered expensive, with a price-to-earnings ratio of 38 and a forward price-to-earnings ratio of 29, necessitating continued rapid growth [15]

公告称，公司和标的公司同属集成电路设计企业，公司主要产品为服务于消费类电子和车载电子领域的 集成电路，主要产品已进入国际主芯片平台厂商、ODM厂商以及三星、小米、荣耀、OPPO、vivo、传 音、谷歌、罗技等品牌客户的消费电子设备供应链体系。而标的公司在集成电路研发设计和封装、测试 的各个环节具有扎实的技术积累，同时拥有强大的销售队伍，建立了广阔的销售渠道，积累了消费电 子、汽车电子等众多领域的客户资源。 公司可通过本次交易快速吸收标的公司成熟的专利技术、研发资源、销售渠道和客户资源等，快速扩大 公司的产品品类，从而有利于公司拓宽在电源管理芯片、电机类芯片、MOSFET和电池管理芯片等领域 的技术与产品布局，为更多下游细分行业客户提供更为完整的解决方案和对应的产品。 希荻微(688173.SH)发布公告，公司拟以现金方式收购曹建林、曹松林、深圳市链智创芯管理咨询合伙 企业(有限合伙)(以下简称"链智创芯")、深圳市汇智创芯管理咨询合伙企业(有限合伙)(以下简称"汇智创 芯")合计持有的深圳市诚芯微科技股份有限公司(以下简称"诚芯微"或"标的公司")100%的股份。本次交 易价格确定为3.1亿元。 ...

Group 1 - The company Yachuang Electronics (301099.SZ) plans to acquire 40% equity in Ouchuangxin and 45% equity in Yihainengda through a combination of share issuance and cash payment, with a transaction price of 317 million yuan [1] - Before the transaction, the company holds 60% equity in Ouchuangxin and 55% equity in Yihainengda, which will become wholly-owned subsidiaries post-transaction [1] - The company intends to raise additional funds by issuing shares to no more than 35 specific investors [1] Group 2 - Ouchuangxin specializes in the research and development of analog chips, focusing on integrated circuit design and sales, particularly in LED lighting drivers and power management chips [2] - Ouchuangxin's products are widely used in the automotive aftermarket for LED lighting, electric two-wheeled vehicles, smart lighting, and emergency firefighting, with a strong market share and brand recognition [2] - The DC-DC power management chips from Ouchuangxin are applicable in various sectors, including electric two-wheeled vehicles and smart home appliances [2] Group 3 - Yihainengda operates as a distributor of electronic components, serving multiple industries such as communications, automotive, industrial control, medical, home appliances, lighting, power supply, security, new energy, and consumer electronics [3] - The company represents a range of products, including passive components, discrete devices, ICs, and modules, and has established long-term partnerships with leading global manufacturers [3] - Yihainengda holds distribution rights for major brands like Murata, Panasonic, TELINK, and Signify [3]